



REINSURANCE **HOT NEWS**

November 18, 2025

AHCCCS is pleased to announce the addition of Vyvgart Hytrulo to the High-Cost Specialty Drug Reinsurance (BIO) effective 10/01/2025:

Vyvgart Hytrulo - (Efgartigimod Alfa & Hyaluronidase-qvfc)- An injection, indicated for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive.

Here is the Link to the Updated High-Cost Specialty Drug List:
<https://www.azahcccs.gov/PlansProviders/Downloads/Reinsurance/BiologicandHighCostSpecialtyDrugList.xlsx>